Autolus Therapeutics (AUTL) Stock Analysis: A Biotech Gem with a 550% Upside PotentialFor investors with a penchant for high-risk, high-reward scenarios, Autolus Therapeutics plc (NASDAQ: AUTL) presents a compelling case. With 10 buy ratings and no holds or sells, there is a strong vote of confidence in the company’s potential. The average target price for AUTL stands impressively at $9.30, suggesting a staggering potential upside of 550.35%. Autolus Therapeutics does not offer a dividend, which is typical for companies in its stage of development, as they reinvest capital to fuel growth. In the high-stakes world of biotechnology, Autolus Therapeutics stands out for its innovative approach and the significant upside potential identified by analysts.